Evidence map›Paper›PMID 34514233›Full record

ArticleACS omega2021

Optical-Property-Enhancing Novel Near-Infrared Active Niosome Nanoformulation for Deep-Tissue Bioimaging.

Suman Bishnoi, Sheeba Rehman, Surjendu Bikash Dutta, Soumya Kanti De, Anjan Chakraborty, Debasis Nayak, Sharad Gupta

Abstract read
In one paragraph

Article in ACS omega, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Suman BishnoiDepartment of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore 453552 Madhya Pradesh, India.ORCID https://orcid.org/0000-0003-2203-0422
Sheeba RehmanDepartment of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore 453552 Madhya Pradesh, India.
Surjendu Bikash DuttaDepartment of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore 453552 Madhya Pradesh, India.
Soumya Kanti DeDepartment of Chemistry, Indian Institute of Technology Indore, Indore 453552 Madhya Pradesh, India.
Anjan ChakrabortyDepartment of Chemistry, Indian Institute of Technology Indore, Indore 453552 Madhya Pradesh, India.ORCID https://orcid.org/0000-0001-5564-0679
Debasis NayakDepartment of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore 453552 Madhya Pradesh, India.ORCID https://orcid.org/0000-0002-4762-4553
Sharad GuptaDepartment of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore 453552 Madhya Pradesh, India.ORCID https://orcid.org/0000-0003-2521-0170

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indocyanine green (ICG) is a clinically approved near-infrared (NIR) contrast agent used in medical diagnosis. However, ICG has not been used to its fullest for biomedical imaging applications due to its low fluorescence quantum yield, aqueous instability, concentration-dependent aggregation, and photo and thermal degradations, leading to quenching of its fluorescence emission. In the present study, a nanosized niosomal formulation, ICGNiosomes (ICGNios), is fabricated to encapsulate and protect ICG from degradation. Interestingly, compared to free ICG, the ICGNios exhibited higher fluorescence quantum yield and fluorescence emission with a bathochromic shift. Also, ICGNios nanoparticles are biocompatible, biodegradable, and readily uptaken by the cells. Furthermore, ICGNios show more enhanced fluorescence intensity through ∼1 cm thick chicken breast tissue compared to free ICG, which showed minimal emission through the same thickness of tissue. Our results suggest that ICGNios could offer a promising platform for deep-tissue NIR

Identifiers

PMID34514233
PMCPMC8427633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.